Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about different treatments for hair loss, including minoxidil, finasteride, RU58841, and dermarolling. The conclusion is that RU58841 and dermarolling have shown efficacy in treating hair loss through different pathways.

The user added RU58841 to their finasteride and minoxidil routine, noticing significant improvement in hairline after 52 days. Some users warn about potential side effects of RU58841, while others express curiosity and congratulate the progress.

The user has been taking oral minoxidil, dutasteride, and biotin for 3 months and noticed changes in hair texture, suggesting potential regrowth or stabilization. Baby hairs and increased hair density are seen as positive signs.

The user is starting a hair loss treatment including topical finasteride/minoxidil, derma rolling, ketoconazole shampoo, vitamins, exercise, and quitting caffeine. They are seeking advice on derma roller needle size, potential side effects, and additional recommendations.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. Concerns were raised about delays in product presentations and business strategies.

A hair loss treatment protocol involving topical and oral medications such as Minoxidil, RU58841, Finasteride, Dutasteride, Melatonin, Zinc, Vitamin B6, NAC, Caffeine, Biotin, Ginseng, and Semen; other treatments including Microneedling, Laser Helmet, Nizoral shampoo, Scalp Massage and supplements like Vitamin C, Vitamin D, Fish Oil, and Biotin; and the potential side effects of using this protocol.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

The conversation criticizes the negative attitude towards those concerned about side effects from hair loss treatments like finasteride and minoxidil, or who prefer natural remedies. Specific treatments discussed include finasteride, minoxidil, rosemary oil, and RU58841, with an agreement that finasteride and minoxidil are proven effective.

A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

The user is seeking opinions on whether their hairline changes indicate regrowth or hair loss, using treatments like Rogaine, finasteride, microneedling, and Nizoral. They mention inconsistent finasteride use, scalp massages, and lifestyle factors like caffeine, nicotine, stress, and high sugar intake.

The user experiences side effects from minoxidil and is considering alternatives like stemoxydine and adenosine for hair regrowth and density, but finds options like caffeine and various oils unreliable. They are also using a 5AR inhibitor (finasteride).

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

The user is considering switching from finasteride and minoxidil to dutasteride for better hair regrowth results, as they are experiencing thinning and shedding despite current treatments. They have also tried microneedling, Clobetasol, and salicylic acid to manage scalp issues and inflammation.

A 20-year-old is using minoxidil and dutasteride for hair regrowth and is questioning if recent changes are due to regrowth or lighting. Users suggest the changes are due to minoxidil and advise not to worry about hair shedding from dutasteride.

The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

A user shared their 3-year progress using 1mg finasteride and 5% topical minoxidil twice daily, reporting significant hair regrowth and some side effects like bloating, seborrheic dermatitis, and water retention. The user is happy with the results, noting improvements in both the crown and hairline.

There are no tests to determine genetic follicle sensitivity for hair loss, and conclusions are based on hypothetical or post-balding observations. Finasteride is mentioned as an easy, consistent treatment option compared to natural treatments.

User is experiencing issues with Minoxidil and is considering switching to Redensyl, specifically asking for brand recommendations. The Ordinary - Multi Peptide is mentioned, but the user seeks other brand experiences.

30 y/o male started balding at 22, began treatment at 29 using oral dut, oral min, derma rolling, nizoral shampoo, and considering low level light therapy. Plans to monitor progress for 1-2 years and may get hair transplant or use hair system if needed.

A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.